Akoustis Technologies Inc Stock
Our community is currently high on Akoustis Technologies Inc with 4 Buy predictions and 1 Sell predictions.
Based on the current price of 0.0 € the target price of 28 € shows a potential of 5599900.0% for Akoustis Technologies Inc which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Akoustis Technologies Inc stock. Criterium "EBIT Margin" gathered the most positive votes but regarding "Credit Rating" there were negative voices in the community.
Pros and Cons of Akoustis Technologies Inc in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
S********** s********
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Akoustis Technologies Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Akoustis Technologies Inc | - | - | - | - | - | - | - |
| Asure Software | -3.620% | 2.222% | -2.128% | -17.857% | -12.658% | -42.975% | -10.968% |
| Overstock.com | 3.420% | -2.326% | -10.811% | -34.468% | -0.581% | -86.042% | -91.943% |
| Egain Communications | 3.450% | 4.505% | 3.571% | 8.411% | -32.164% | -10.078% | -39.267% |
Comments
Aktis Oncology (AKTS) was downgraded by Wall Street Zen from "hold" to "sell".
Show more
Ratings data for AKTS provided by MarketBeat
Aktis Oncology (AKTS) had its price target raised by JPMorgan Chase & Co. from $30.00 to $33.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for AKTS provided by MarketBeat
Aktis Oncology (AKTS) had its "buy" rating reaffirmed by HC Wainwright.
Show more
Ratings data for AKTS provided by MarketBeat